Frank Nocken: FDA Approves Caplacizumab Therapy for Pediatric Acquired TTP
Frank Nocken, Independent Consultant for Scientific Innovation Management, shared a post on LinkedIn:
“‘The FDA has approved Cablivi (caplacizumab) for injection to treat pediatric patients aged 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.’
‘Caplacizumab therapy is nanobody-based and built on small antibody fragments derived from heavy-chain-only antibodies, that targets von Willebrand factor, a protein that plays a central role in platelet adhesion and clot formation in aTTP.
It works by binding to the A1 domain of von Willebrand factor, blocking its interaction with platelets and helping to reduce the microvascular clots that define the disease.'”
Stay updated with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies